Kelley-Ross & Associates, Inc. dba Kelley-Ross Compounding Pharmacy – FDA 483, Sep 23, 2020
An FDA inspection of Kelley-Ross & Associates, Inc. dba Kelley-Ross Compounding Pharmacy in Seattle, WA, revealed significant deficiencies in both sterile and non-sterile drug production. Observations included inadequate disinfection of materials, poor facility design allowing air quality issues, visibly dirty aseptic processing areas, improper personnel gowning, and insufficient cleaning procedures for equipment used with hazardous drugs, raising concerns about product sterility and cross-contamination.
- Inspection date
- September 23, 2020
- Product type
- drugs
ID · 9baaf485-bf9d-48a4-a901-a97da5908536
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.